<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Steroid hormone metabolism in polycystic ovary syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Steroid hormone metabolism in polycystic ovary syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Steroid hormone metabolism in polycystic ovary syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Crowley, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Polycystic ovary syndrome (PCOS) is characterized clinically by menstrual dysfunction, including oligo- or anovulation and signs of hyperandrogenism [<a href="#rid1">1</a>]. This review will describe the abnormalities in steroid hormones that are present in this disorder, including the factors responsible for the increase in androgen production. The clinical manifestations of PCOS are discussed separately. (See  <a class="medical medical_review" href="/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ANDROGEN METABOLISM</span><span class="headingEndMark"> — </span>As a group, women with PCOS have serum concentrations of testosterone, free testosterone, androstenedione, dehydroepiandrosterone (DHEA), and DHEA sulfate (DHEAS) that are significantly elevated compared with ovulatory, nonhirsute women  (<a class="graphic graphic_figure graphicRef72842" href="/d/graphic/72842.html" rel="external">figure 1</a>)<strong> </strong>[<a href="#rid1">1,2</a>]. There is, however, significant individual variation, and some women with PCOS may have normal androgen levels when assayed in a single blood specimen [<a href="#rid1">1</a>]. </p><p>In women, androgens are produced by the adrenal glands and the ovaries, as well as by conversion of less potent to more potent androgens in the periphery. The source of the major androgens in PCOS is shown in the table  (<a class="graphic graphic_table graphicRef60049" href="/d/graphic/60049.html" rel="external">table 1</a>). In PCOS, androstenedione and testosterone are secreted primarily by the ovaries  (<a class="graphic graphic_figure graphicRef57364" href="/d/graphic/57364.html" rel="external">figure 2</a>) and, to a lesser degree, the adrenals. This pattern differs from that in ovulatory premenopausal women who have approximately equal androstenedione and testosterone production from the ovaries and the adrenals [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H3"><span class="h2">Testosterone</span><span class="headingEndMark"> — </span>Testosterone is the most potent circulating androgen. Its biologic activity is determined by three factors: its concentration, the amount of binding to sex hormone-binding globulin (SHBG), as only the free fraction is active, and by the intracellular rate of conversion of testosterone by the 5-alpha reductase enzyme to the potent i androgen, dihydrotestosterone (DHT) (see <a class="local">'Dihydrotestosterone'</a> below). Unlike testosterone, which is a circulating androgen, dihydrotestosterone is an intracellular androgen. Liver production of SHBG concentrations is regulated by androgens (decrease), estrogens (increase), and insulin (decrease) [<a href="#rid4">4</a>]. Thus, hyperandrogenic women with PCOS, especially if obese or insulin resistant, tend to have low serum SHBG concentrations. When SHBG is low or low-normal, a serum testosterone within the upper end of the normal range may be associated with excess androgen stimulation in target tissues because of elevated free testosterone.</p><p>Body mass index (BMI) is positively correlated with serum total testosterone and inversely correlated with SHBG concentrations in women of all reproductive ages regardless of their ovulatory status.</p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort study of 1526 Scandinavian premenopausal women (mean age 31 years), increasing BMI was associated with increased serum testosterone and decreased serum SHBG concentrations in both ovulatory and oligo-ovulatory women [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar associations were observed in the Study of Women's Health Across the Nation (SWAN) of 2930 perimenopausal women (mean age 46 years) [<a href="#rid6">6</a>] and in a study of menopausal women [<a href="#rid7">7</a>].</p><p></p><p>Cigarette smoking is associated with increased serum testosterone concentrations in premenopausal women [<a href="#rid6">6,8</a>]. It is not known if discontinuing smoking is associated with a subsequent decrease in serum testosterone.</p><p class="headingAnchor" id="H4"><span class="h2">Androstenedione</span><span class="headingEndMark"> — </span>Androstenedione is the immediate precursor to testosterone. Androstenedione is converted to testosterone by the 17-beta-hydroxysteroid dehydrogenase (17-ketosteroid reductase) enzyme, which is present in most tissues. In the ovary of ovulatory women, the theca cells secrete significant quantities of androstenedione, which enters the granulosa cells and is converted to <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> and estradiol. Luteinizing hormone (LH) directly stimulates thecal secretion of androstenedione. In PCOS, LH levels are elevated so the theca secretes increased quantities of androstenedione. In addition, thecal cells from women with PCOS are more sensitive to LH stimulation of androgen production [<a href="#rid9">9</a>]. The androstenedione secreted into the circulation by the ovary and adrenal can be converted to the potent androgen, testosterone, by most peripheral tissues.</p><p class="headingAnchor" id="H5"><span class="h2">Dehydroepiandrosterone sulfate</span><span class="headingEndMark"> — </span>The majority of DHEAS derives from the adrenal glands, and there is little, if any, sulfotransferase (sulfokinase) activity in the periphery to convert DHEA to DHEAS. As a result, the serum concentration of DHEAS is a good marker of adrenal androgen hypersecretion. In addition, since DHEAS has a long serum half-life, with minimal pulsatile or diurnal variation, a single measurement of serum DHEAS correlates well with integrated measures of DHEAS secretion.</p><p>However, some adrenocortical carcinomas have no sulfotransferase activity, and some patients with congenital adrenal hyperplasia have normal DHEAS levels. Thus, normal serum DHEAS concentrations do not necessarily exclude a pathologic adrenal source of excess androgens.</p><p>Although DHEA and DHEAS are markers of adrenal androgen production, they have little if any intrinsic androgenic activity. Small amounts are converted to androstenedione and then to testosterone (and to estrogen) in both the adrenal glands and peripheral tissues, including hair follicles and external genitalia. Thus, the hirsutism and virilization that may occur in patients with adrenal hyperandrogenism are caused by androstenedione and testosterone. (See  <a class="medical medical_review" href="/d/html/123.html" rel="external">"Adrenal hyperandrogenism"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Dihydrotestosterone</span><span class="headingEndMark"> — </span>Testosterone binds to the intracellular androgen receptor with modest affinity. In androgen-responsive tissues, intracellular 5-alpha reductase converts testosterone to DHT. DHT binds to the androgen receptor with an affinity 10 times greater than testosterone. There are multiple subtypes of 5-alpha reductase. In a tissue such as the prostate, the type II isoenzyme predominates, while in the pilosebaceous unit, both the type I and II isoforms are present. Women with PCOS have increased 5-alpha reductase activity [<a href="#rid10">10</a>], resulting in increased activation of the pilosebaceous unit (hair growth, sebum production) with only modest increases in bioavailable testosterone. </p><p class="headingAnchor" id="H7"><span class="h2">Androstanediol</span><span class="headingEndMark"> — </span>3-alpha-androstanediol-glucuronide (3aA-G) is derived from the metabolism of the potent intracellular androgen DHT. It can therefore be used as a marker of peripheral androgen metabolism. Serum concentrations of 3aA-G are almost uniformly high in women with hirsutism. Urine concentrations of 3-aA-G are elevated in women with PCOS [<a href="#rid11">11</a>]. Except for research purposes, however, it is probably unnecessary to measure 3aA-G as the presence of hirsutism by definition indicates that androgen activity in the skin is increased.</p><p class="headingAnchor" id="H8"><span class="h1">ESTROGEN METABOLISM</span><span class="headingEndMark"> — </span>Most women with PCOS have serum estradiol concentrations similar to the early follicular phase of ovulatory women and elevated serum <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> concentrations  (<a class="graphic graphic_figure graphicRef52544" href="/d/graphic/52544.html" rel="external">figure 3</a>)<strong> </strong>[<a href="#rid1">1,2</a>]. The serum estrogens in women with PCOS come partly from the multiple small follicles in the polycystic ovaries and partly from aromatization of androgens to estrogens in fat cells.</p><p>The net effect is that PCOS is a normoestrogenic state, and estrogen replacement is not required, even in amenorrheic women with PCOS. Women with PCOS are oligo- or anovulatory and do not produce normal quantities of progesterone. Consequently, they are at an increased risk of endometrial hyperplasia and heavy menstrual bleeding. (See  <a class="medical medical_review" href="/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">CONTROL OF ANDROGEN PRODUCTION</span><span class="headingEndMark"> — </span>The control of androgen production in women is complex because the androgens are produced in multiple sites. In both the ovaries and adrenal glands, androgen secretion requires the activity of multiple steroidogenic enzymes  (<a class="graphic graphic_figure graphicRef71558" href="/d/graphic/71558.html" rel="external">figure 4</a>), including:</p><p class="bulletIndent1"><span class="glyph">●</span>Cholesterol synthesis – All gonadal steroid synthesis begins with synthesis of cholesterol and its transport to steroidogenic tissues in lipoproteins. In placebo-controlled trials, the cholesterol synthesis inhibitor <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> (20 mg/day) reduced hyperandrogenemia when administered to women with PCOS [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>P450scc (side-chain cleavage) that converts cholesterol to pregnenolone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>3-beta-hydroxysteroid dehydrogenase that converts steroids such as pregnenolone, 17-hydroxypregnenolone, and dehydroepiandrosterone (DHEA) to progesterone, 17-hydroxyprogesterone, and androstenedione.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>P450c17, which has both 17-hydroxylation and 17,20 lyase functions and, therefore, converts pregnenolone to 17-hydroxypregnenolone and 17-hydroxypregnenolone to DHEA, and progesterone to 17-hydroxyprogesterone and 17-hydroxyprogesterone to androstenedione, respectively.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Ovarian androgen secretion</span><span class="headingEndMark"> — </span>Ovarian androgens are produced in the theca cells, which respond to luteinizing hormone (LH) [<a href="#rid13">13</a>]. Theca cells synthesize mostly androstenedione and some testosterone, which diffuse across the basement membrane to the granulosa cells. The granulosa cells, in response to stimulation by follicle-stimulating hormone (FSH), produce aromatase, which converts the androgen precursors to <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> and estradiol  (<a class="graphic graphic_figure graphicRef76006" href="/d/graphic/76006.html" rel="external">figure 5</a>) [<a href="#rid13">13</a>].</p><p>In women with PCOS, ovarian androgen production may increase as a result of one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>An increased volume of theca cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased LH stimulation of the theca cells. Indirect support for the "excess LH drive" hypothesis derives from transgenic animal studies. Overexpression of human chorionic gonadotropin (hCG) (which binds and activates the same receptor as LH) resulted in mice with large cystic ovaries [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased theca cell sensitivity to LH stimulation [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potentiation of the action of LH by hyperinsulinemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Production of beta subunits of LH that have different biological activity as a result of polymorphism of the gene for the subunit [<a href="#rid15">15</a>]. The more active LH need not be more immunoreactive, so serum LH concentrations as routinely measured might be normal (and often are normal) in these women.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased expression of LH receptor, CYP11A, and CYP17 mRNAs in thecal cells from PCOS follicles versus size-matched control follicles [<a href="#rid16">16</a>]. In addition, theca cells from the ovaries of women with PCOS demonstrate increased CYP17 and 3-beta hydroxysteroid dehydrogenase enzyme activity [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Role of insulin</span><span class="headingEndMark"> — </span>In vitro experiments with human theca cells have demonstrated a synergistic effect of LH and insulin to increase androgen secretion [<a href="#rid17">17</a>]. Several studies in obese women with PCOS are compatible with a contributory role of insulin. As an example, reducing the degree of insulin resistance with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> [<a href="#rid18">18</a>] or reducing insulin secretion with <a class="drug drug_general" data-topicid="9346" href="/d/drug information/9346.html" rel="external">diazoxide</a> [<a href="#rid19">19</a>] results in a fall in serum androgen concentrations.</p><p>The association of insulin resistance with hyperinsulinemia in women with PCOS results in the "insulin paradox" since a resistant organ should not be able to hyper-respond. Several hypotheses have been proposed to explain this paradox:</p><p class="bulletIndent1"><span class="glyph">●</span>The high serum insulin concentrations may activate the homologous receptors for insulin-like growth factors-1 and -2 (IGF-1 and IGF-2). This argument is tenable for women with extreme insulin resistance syndromes who have very high serum insulin concentrations. However, women with PCOS usually have only mildly elevated serum insulin concentrations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There may be hybrid receptors in which a half-insulin receptor dimerizes with a half-IGF-1 receptor  (<a class="graphic graphic_figure graphicRef61896" href="/d/graphic/61896.html" rel="external">figure 6</a>). This hypothesis has not yet been demonstrated in women with PCOS.</p><p></p><p>Regardless of the mechanism, it appears that some women with PCOS have insulin resistance in muscle, adipose tissue, and liver but demonstrate insulin sensitivity in the ovary. A 1995 report described a woman with PCOS and severe insulin resistance (in terms of glucose metabolism) in whom ovarian insulin sensitivity was normal [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H3950723810"><span class="h3">Role of anti-müllerian hormone</span><span class="headingEndMark"> — </span>Anti-müllerian hormone (AMH) circulating levels are increased in women with PCOS [<a href="#rid21">21</a>]. AMH may attenuate FSH stimulation of follicle growth [<a href="#rid22">22</a>] and decrease aromatase enzyme activity, thereby inhibiting estradiol production [<a href="#rid23">23</a>]. Elevated AMH is likely detrimental to the process of follicle development and may contribute to the androgen dominant milieu detected in the follicles of women with PCOS by reducing the rate of conversion of androstenedione and testosterone to <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> and estradiol, respectively.</p><p class="headingAnchor" id="H12"><span class="h3">Other factors</span><span class="headingEndMark"> — </span>Other factors that can increase ovarian androgen secretion in women with PCOS include:</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased aromatase activity due to decreased FSH secretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A decreased number of maturing follicles to "deactivate" the androgens to estrogens. However, the granulosa cells from the small follicles of PCOS ovaries usually maintain the ability to aromatize androgens to estrogens in response to FSH [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dysregulated ovarian androgen secretion. An increased serum 17-hydroxyprogesterone response to gonadotropins in hyperandrogenic women suggests that there is dysregulated function of the P450c17 enzyme in the ovaries [<a href="#rid25">25</a>]; the dysfunction may be intrinsic to the thecal cells [<a href="#rid26">26</a>]. In theca cells from women with PCOS, mRNA transcripts for P450c17 have an increased half-life [<a href="#rid27">27</a>]. In addition, these cells appear to have alterations in pathways of mitogen-activated protein kinase and extracellular regulated kinase signaling that enhance P450c17 activity [<a href="#rid28">28</a>].</p><p></p><p>As noted above, P450c17 catalyzes both 17-hydroxylation and 17,20-lyase reactions; however, it can be selectively induced to increase its 17,20-lyase activity (thereby producing more androgens) by serine phosphorylation [<a href="#rid29">29</a>].</p><p>In theca cells from women with PCOS, GATA6, a transcription factor that increases expression of multiple steroidogenic enzymes, has increased activity [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Adrenal androgen secretion</span><span class="headingEndMark"> — </span>Adrenal steroidogenesis is a complex process under the control of corticotropin (ACTH), as well as other factors  (<a class="graphic graphic_figure graphicRef71558" href="/d/graphic/71558.html" rel="external">figure 4</a>). ACTH has a primary role in controlling the rate-limiting step of adrenal steroidogenesis, the cholesterol side-chain cleavage enzyme, leading to increased secretion of adrenal androgens as well as glucocorticoids and mineralocorticoids.</p><p>Over 50 percent of women with PCOS have evidence of increased adrenal androgen secretion including hyper-responsivity of adrenal steroidogenesis to exogenous ACTH administration [<a href="#rid31">31</a>]. This increased adrenal androgen secretion is not due to subtle defects in CYP21 [<a href="#rid32">32</a>]. During the normal aging process in males and females, adrenal androgen secretion decreases. Based on the results from one small study, women with PCOS demonstrate excess adrenal androgen secretion with no age-related decrease into the onset of menopause [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Other</span><span class="headingEndMark"> — </span>There is evidence that other factors can contribute to the regulation of androgen synthesis in PCOS. One important factor may be genetic predisposition. Familial cases of PCOS have been described, although the underlying defect is not known [<a href="#rid34">34,35</a>]. In addition, there is evidence for abnormalities of steroidogenic enzyme function, which may be related to feedback from intraglandular steroid levels, modification of cofactor function, or unknown mechanisms [<a href="#rid25">25,36-39</a>].</p><p>In women with PCOS, steroid hormone concentrations may be influenced by genetic traits. For example, the single nucleotide polymorphism (SNP) rs182420 in the DHEA sulfotransferase enzyme (SULT2A1, which converts DHEA to DHEA sulfate [DHEAS]) is associated with increased circulating levels of DHEAS, and the promoter variant 1C in the enzyme CYP3A7, which degrades DHEAS through 16-hydroxylation, is associated with reduced levels of circulating DHEAS [<a href="#rid40">40,41</a>].</p><p>In the largest, most comprehensive association study of PCOS genotype, mutations in the region of the FSH-beta gene were identified that positively correlate with an elevation in circulating LH concentration [<a href="#rid42">42</a>]. In turn, elevated LH stimulates ovarian androgen production. (See  <a class="medical medical_review" href="/d/html/7430.html" rel="external">"Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults"</a>.)</p><p class="headingAnchor" id="H2906096740"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110097.html" rel="external">"Society guideline links: Polycystic ovary syndrome"</a>.)</p><p class="headingAnchor" id="H3109666"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Polycystic ovary syndrome (PCOS) is characterized by excessive secretion of androgens from the ovary and, in many cases, the adrenal gland. Approximately 75 percent of women with PCOS have an elevated concentration of circulating free testosterone, total testosterone, or dehydroepiandrosterone sulfate (DHEAS).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with PCOS typically have elevated pituitary secretion of luteinizing hormone (LH), which stimulates the ovarian theca cells to secrete excess quantities of androstenedione, an androgen precursor that can be metabolized to testosterone, a potent circulating androgen. Circulating testosterone is converted to dihydrotestosterone (DHT), the most potent intracellular androgen, in target tissues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sex hormone-binding globulin (SHBG) is the major high-affinity circulating binding protein for testosterone. Testosterone bound to SHBG is believed to not be bioavailable to tissues. Free testosterone and testosterone weakly bound to albumin are thought to be available to stimulate androgen activity in target tissues such as the hair follicle. In PCOS, hyperandrogenism and hyperinsulinemia due to insulin resistance reduce hepatic production of SHBG and decrease circulating SHBG levels. The decrease in SHBG results in a proportionate increase in free testosterone, increasing testosterone bioactivity, and, at the same time, decreasing total testosterone levels.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Zawadzki JK, Dunaif A. Diagnostic criteria for PCOS: towards a rational approach. In: PCOS: current issues in endocrinology and metabolism, Dunaif A, Givens JR, Hazeltine FP, Merriam GR (Eds), Blackwell Scientific, Boston 1992. Vol 4, p.235.</li><li><a class="nounderline abstract_t">DeVane GW, Czekala NM, Judd HL, Yen SS. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 1975; 121:496.</a></li><li><a class="nounderline abstract_t">Longcope C. Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 1986; 15:213.</a></li><li><a class="nounderline abstract_t">Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72:83.</a></li><li><a class="nounderline abstract_t">Taponen S, Martikainen H, Järvelin MR, et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab 2003; 88:141.</a></li><li><a class="nounderline abstract_t">Randolph JF Jr, Sowers M, Gold EB, et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003; 88:1516.</a></li><li><a class="nounderline abstract_t">Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95:1218.</a></li><li><a class="nounderline abstract_t">Sowers MF, Beebe JL, McConnell D, et al. Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composition, and ovarian status. Am J Epidemiol 2001; 153:256.</a></li><li><a class="nounderline abstract_t">Rosencrantz MA, Coffler MS, Haggan A, et al. Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96:1106.</a></li><li><a class="nounderline abstract_t">Vassiliadi DA, Barber TM, Hughes BA, et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94:3558.</a></li><li><a class="nounderline abstract_t">Dhayat NA, Marti N, Kollmann Z, et al. Urinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary syndrome: A pilot study considering neglected steroid metabolites. PLoS One 2018; 13:e0203903.</a></li><li><a class="nounderline abstract_t">Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 2009; 94:103.</a></li><li><a class="nounderline abstract_t">Erickson GF, Magoffin DA, Dyer CA, Hofeditz C. The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev 1985; 6:371.</a></li><li><a class="nounderline abstract_t">Risma KA, Clay CM, Nett TM, et al. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci U S A 1995; 92:1322.</a></li><li><a class="nounderline abstract_t">Tapanainen JS, Koivunen R, Fauser BC, et al. A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. J Clin Endocrinol Metab 1999; 84:1711.</a></li><li><a class="nounderline abstract_t">McAllister JM, Legro RS, Modi BP, Strauss JF 3rd. Functional genomics of PCOS: from GWAS to molecular mechanisms. Trends Endocrinol Metab 2015; 26:118.</a></li><li><a class="nounderline abstract_t">Barbieri RL, Makris A, Ryan KJ. Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet Gynecol 1984; 64:73S.</a></li><li><a class="nounderline abstract_t">Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617.</a></li><li><a class="nounderline abstract_t">Nestler JE, Barlascini CO, Matt DW, et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989; 68:1027.</a></li><li><a class="nounderline abstract_t">Willis D, Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 1995; 80:3788.</a></li><li><a class="nounderline abstract_t">Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online 2016; 33:15.</a></li><li><a class="nounderline abstract_t">Pellatt L, Rice S, Dilaver N, et al. Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril 2011; 96:1246.</a></li><li><a class="nounderline abstract_t">Chang HM, Klausen C, Leung PC. Antimüllerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells. Fertil Steril 2013; 100:585.</a></li><li><a class="nounderline abstract_t">Mason HD, Willis DS, Beard RW, et al. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. J Clin Endocrinol Metab 1994; 79:1355.</a></li><li><a class="nounderline abstract_t">Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989; 320:559.</a></li><li><a class="nounderline abstract_t">Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997; 47:93.</a></li><li><a class="nounderline abstract_t">Wickenheisser JK, Nelson-Degrave VL, McAllister JM. Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:1720.</a></li><li><a class="nounderline abstract_t">Nelson-Degrave VL, Wickenheisser JK, Hendricks KL, et al. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol 2005; 19:379.</a></li><li><a class="nounderline abstract_t">Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A 1995; 92:10619.</a></li><li><a class="nounderline abstract_t">Ho CK, Wood JR, Stewart DR, et al. Increased transcription and increased messenger ribonucleic acid (mRNA) stability contribute to increased GATA6 mRNA abundance in polycystic ovary syndrome theca cells. J Clin Endocrinol Metab 2005; 90:6596.</a></li><li><a class="nounderline abstract_t">Azziz R, Black V, Hines GA, et al. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 1998; 83:2317.</a></li><li><a class="nounderline abstract_t">Glintborg D, Hermann AP, Brusgaard K, et al. Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J Clin Endocrinol Metab 2005; 90:1347.</a></li><li><a class="nounderline abstract_t">Puurunen J, Piltonen T, Jaakkola P, et al. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94:1973.</a></li><li><a class="nounderline abstract_t">Hague WM, Adams J, Reeders ST, et al. Familial polycystic ovaries: a genetic disease? Clin Endocrinol (Oxf) 1988; 29:593.</a></li><li><a class="nounderline abstract_t">Givens JR. Familial polycystic ovarian disease. Endocrinol Metab Clin North Am 1988; 17:771.</a></li><li><a class="nounderline abstract_t">Lucky AW, Rosenfield RL, McGuire J, et al. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 1986; 62:840.</a></li><li><a class="nounderline abstract_t">Toscano V, Balducci R, Bianchi P, et al. Ovarian 17-ketosteroid reductase deficiency as a possible cause of polycystic ovarian disease. J Clin Endocrinol Metab 1990; 71:288.</a></li><li><a class="nounderline abstract_t">Vermesh M, Silva PD, Rosen GF, et al. Effect of androgen on adrenal steroidogenesis in normal women. J Clin Endocrinol Metab 1988; 66:128.</a></li><li><a class="nounderline abstract_t">Ehrmann DA, Rosenfield RL, Barnes RB, et al. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992; 327:157.</a></li><li><a class="nounderline abstract_t">Goodarzi MO, Antoine HJ, Azziz R. Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:2659.</a></li><li><a class="nounderline abstract_t">Goodarzi MO, Xu N, Azziz R. Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:2909.</a></li><li><a class="nounderline abstract_t">Hayes MG, Urbanek M, Ehrmann DA, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun 2015; 6:7502.</a></li></ol></div><div id="topicVersionRevision">Topic 7442 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Zawadzki JK, Dunaif A. Diagnostic criteria for PCOS: towards a rational approach. In: PCOS: current issues in endocrinology and metabolism, Dunaif A, Givens JR, Hazeltine FP, Merriam GR (Eds), Blackwell Scientific, Boston 1992. Vol 4, p.235.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/125040" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3013468" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adrenal and gonadal androgen secretion in normal females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1898744" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519843" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679432" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12928347" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157413" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composition, and ovarian status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21270326" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19567518" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30308019" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Urinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary syndrome: A pilot study considering neglected steroid metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18940877" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3896767" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The ovarian androgen producing cells: a review of structure/function relationships.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7877975" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10323405" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25600292" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Functional genomics of PCOS: from GWAS to molecular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6382082" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8687515" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2498378" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8530637" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27174394" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The role of AMH in the pathophysiology of polycystic ovarian syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917251" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23663993" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antimüllerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962330" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2521688" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9302378" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598676" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15514033" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7479852" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16159937" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Increased transcription and increased messenger ribonucleic acid (mRNA) stability contribute to increased GATA6 mRNA abundance in polycystic ovary syndrome theca cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661602" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598692" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19318449" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3076848" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Familial polycystic ovaries: a genetic disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3058473" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Familial polycystic ovarian disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3007557" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2166066" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ovarian 17-ketosteroid reductase deficiency as a possible cause of polycystic ovarian disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2826523" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of androgen on adrenal steroidogenesis in normal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1319000" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Detection of functional ovarian hyperandrogenism in women with androgen excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426092" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445661" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26284813" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
